Inovio Pharmaceuticals, Inc. (INO) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Inovio Pharmaceuticals, Inc. (INO) Earnings Overview
As of June 28, 2026, Inovio Pharmaceuticals, Inc. (INO) reported trailing twelve-month net income of -$85M, reflecting +54.2% year-over-year growth. The company earned $-0.12 per diluted share over the past four quarters, with a net profit margin of -130000.0%.
Looking at the long-term picture, INO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2003.
Inovio Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NVAX (-$88M net income, 39.2% margin), OCGN (-$72M net income, -1537.4% margin), DVAX (-$43M net income, 9.9% margin), INO has room to improve margins relative to the peer group. Compare INO vs NVAX →
INO Earnings vs Peers
Earnings metrics vs comparable public companies
INO Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$85M | +20.8% | -$87M | $-1.81 | -130000.0% | -132871.3% |
| 2024 | -$107M | +20.6% | -$112M | $-3.95 | -49254.3% | -51616.9% |
| 2023 | -$135M | +51.7% | -$144M | $-6.09 | -16239.9% | -17300.3% |
| 2022 | -$280M | +7.9% | -$268M | $-14.07 | -2726.7% | -2607.4% |
| 2021 | -$304M | -82.5% | -$301M | $-1.42 | -17109.9% | -16972.3% |
| 2020 | -$166M | -39.4% | -$124M | $-1.07 | -2245.4% | -1674.2% |
| 2019 | -$119M | -23.1% | -$111M | $-0.97 | -2902.8% | -2702.1% |
| 2018 | -$97M | -9.9% | -$94M | $-1.05 | -318.1% | -308.7% |
| 2017 | -$88M | -19.6% | -$84M | $-1.08 | -208.9% | -198.1% |
| 2016 | -$74M | -152.6% | -$76M | $-1.01 | -208.5% | -215.5% |
| 2015 | -$29M | +19.2% | -$34M | $-0.43 | -71.9% | -84.5% |
| 2014 | -$36M | +45.3% | -$39M | $-0.61 | -345.4% | -377.7% |
| 2013 | -$66M | -235.7% | -$20M | $-1.43 | -490.3% | -145.1% |
| 2012 | -$20M | -29.0% | -$23M | $-0.58 | -477.6% | -570.4% |
| 2011 | -$15M | +13.4% | -$22M | $-0.48 | -155.7% | -220.9% |
| 2010 | -$18M | +27.8% | -$19M | $-0.68 | -286.6% | -312.8% |
| 2009 | -$24M | -88.3% | -$14M | $-1.31 | -267.7% | -153.0% |
| 2008 | -$13M | -15.7% | -$14M | $-1.18 | -618.1% | -651.1% |
| 2007 | -$11M | +10.2% | -$16M | $-1.08 | -233.1% | -330.7% |
| 2006 | -$12M | +18.4% | -$13M | $-1.58 | -359.8% | -384.8% |
| 2005 | -$15M | -39.4% | -$16M | $-3.22 | -279.8% | -283.6% |
| 2004 | -$11M | -135.2% | -$12M | $-2.49 | -940.2% | -986.3% |
| 2003 | -$5M | +21.8% | -$7M | $-1.40 | -5792.8% | -8237.1% |
| 2002 | -$6M | +32.7% | -$6M | $-2.35 | -3147.3% | -3131.5% |
| 2001 | -$9M | +7.6% | -$6M | $-5.13 | -199.1% | -125.2% |
| 2000 | -$10M | -45.5% | -$10M | $-6.80 | -189.1% | -187.8% |
| 1999 | -$7M | - | -$7M | $-5.21 | -79.5% | -83.1% |
Download Data
Export INO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INO — Frequently Asked Questions
Quick answers to the most common questions about buying INO stock.
What is INO earnings per share (EPS)?
INO trailing twelve-month (TTM) diluted EPS is $-0.12, reflecting +54.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Inovio Pharmaceuticals, Inc.'s net income?
Inovio Pharmaceuticals, Inc. (INO) trailing twelve-month net income is $-85M as of 2025. Earnings grew +54.2% year-over-year.
Is INO profitable?
INO is not currently profitable on a TTM basis, reporting a net loss of $-85M. Net margin is -130000.0%. Investors should monitor for a return to profitability.
What is INO's earnings growth rate?
INO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are INO's profit margins?
Inovio Pharmaceuticals, Inc. net profit margin is -130000.0%, operating margin is -132871.3%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -183.5%.
Is INO growing earnings?
Yes, INO earnings are accelerating — EPS growth of +54.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-85M. Earnings momentum is strengthening.
What was INO's best earnings year?
Inovio Pharmaceuticals, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2003. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were INO's earnings last quarter?
INO's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-0.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.